Sphera Funds Management Ltd. Xenon Pharmaceuticals Inc. Transaction History

Sphera Funds Management Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $1.33 Million - $1.55 Million	38,959 New	38,959 $1.33 Million
Q4 2021 Feb 14, 2022	SELL	$15.6 - $35.4 $5.83 Million - $13.2 Million	-373,510 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$14.86 - $19.45 $1.45 Million - $1.89 Million	97,380 Added 35.27%	373,510 $5.71 Million
Q2 2021 Aug 17, 2021	SELL	$16.81 - $20.0 $4.33 Million - $5.15 Million	-257,525 Reduced 48.26%	276,130 $51.4 Million
Q1 2019 May 15, 2019	BUY	$6.39 - $10.42 $537,852 - $877,061	84,171 Added 18.73%	533,655 $5.42 Million
Q4 2018 Feb 14, 2019	BUY	$5.61 - $12.62 $392,700 - $883,400	70,000 Added 18.45%	449,484 $2.84 Million
Q3 2018 Nov 14, 2018	SELL	$9.0 - $14.9 $535,950 - $887,295	-59,550 Reduced 13.56%	379,484 $5.01 Million
Q2 2018 Aug 13, 2018	BUY	$4.8 - $9.2 $2.11 Million - $4.04 Million	439,034 New	439,034 $4.04 Million
Q4 2017 Feb 12, 2018	SELL	$2.2 - $3.25 $501,663 - $741,094	-228,029 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$2.45 - $3.25 $558,671 - $741,094	228,029	228,029 $673,000

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.